Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

152.86 +0.43 (+0.28%)
Streaming Delayed Price Updated: 12:08 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Expert Ratings for Charles River ↗
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
News headline image
Charles River Laboratories Expands Contract Vivarium Space on West Coast
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Recap: Charles River Q2 Earnings ↗
  Charles River (NYSE:CRL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗
Upgrades 
Via Benzinga
News headline image
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks ↗
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
News headline image
Analyst Ratings for Charles River ↗
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
News headline image
Charles River: Q1 Earnings Insights ↗
Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
From Charles River Laboratories, International Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022 ↗
Upgrades 
Via Benzinga
News headline image
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday ↗
  Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results. 
Via Benzinga
News headline image
Charles River Laboratories Announces Second-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
'I'm Going To Have To Say Avoid It': Jim Cramer Urges Waiting Before Buying This Tech Stock ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Charles River Laboratories International Inc (NYSE: CRL). 
Via Benzinga
News headline image
Where Charles River Stands With Analysts ↗
Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Charles River Laboratories Announces First-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Preview: Charles River's Earnings ↗
Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River... 
Via Benzinga
News headline image
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
3 Top S&P 500 Stock Market Gainers Today: Coronavirus Vaccine Maker Moderna Jumps ↗
Moderna led big-cap winners Monday. Oil services giants were losers. 
Via Investor's Business Daily
News headline image
Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know ↗
Wells Fargo has decided to maintain its Overweight rating of Charles River (NYSE:CRL) and lower its price target from $390.00 to $325.00. Shares of Charles River are trading down 7.96% over the last 24... 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Charles River ↗
Analysts have provided the following ratings for Charles River (NYSE:CRL) within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022 ↗
 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading. 
Via Benzinga
News headline image
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.